title: Ingested (oral) anti-IL-12/23 inhibits EAE.
abstract: BACKGROUND
  Blocking the activity of IL-12/23 can inhibit autoimmune diseases such as psoriasis.
  
  
  OBJECTIVE
  We examined whether an antibody against IL-12/23, ustekinumab (UTZ) (Stelera®), used clinically in psoriasis would have similar anti-inflammatory effects in EAE after oral administration.
  
  
  METHODS
  B6 mice were immunized with MOG peptide 35-55 and gavaged with isotype IgG control or UTZ during ongoing disease. Splenocytes, CD4(+) T cells or macrophages/monocyte lineage cells (CD11b(+)) from control fed or UTZ fed mice were adoptively transferred into active MOG peptide 35-55 immunized recipient mice during ongoing disease. Actively fed and recipient mice were examined for disease inhibition, inflammation, and cytokine responses.
  
  
  RESULTS
  Ingested (oral) UTZ inhibited ongoing disease and decreased inflammation. Adoptively transferred cells from UTZ fed donors protected against actively induced disease and decreased inflammation. Oral UTZ decreased pro-inflammatory cytokines Th1-like cytokines IL-2, IL-12, IFN-γ, IL-17 (Teff) and TNF-α in UTZ fed mice and increased counter-regulatory cytokines IL-4, IL-10 and IL-13 in recipients of donor cells from UTZ fed mice.
  
  
  CONCLUSIONS
  Ingested (orally administered) UTZ can inhibit disease, CNS inflammation, decrease pro-inflammatory Th1-like and Th17 cytokines and increase Th2-like anti-inflammatory cytokines.
authors.affiliation: Department of Neurology, Division of MS/Neuroimmunology, Medical College of Wisconsin, 8701 W Watertown Plank Rd, Milwaukee, WI 53226, USA. Electronic address: sbrod@mac.com.
authors.forename: Staley A
authors.initials: SA
authors.lastname: Brod
mesh_terms: D000284:Administration, Oral; D019264:Adoptive Transfer; D000818:Animals; D016207:Cytokines / Q000378:metabolism; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000188:drug therapy* / Q000276:immunology; D051379:Mice; D009000:Monocytes / Q000187:drug effects* / Q000276:immunology; D013116:Spinal Cord / Q000187:drug effects / Q000378:metabolism; D013154:Spleen / Q000187:drug effects / Q000378:metabolism; D018417:Th1 Cells / Q000187:drug effects* / Q000276:immunology; D058504:Th17 Cells / Q000187:drug effects* / Q000276:immunology; D000069549:Ustekinumab / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D016207:Cytokines; D000069549:Ustekinumab
keywords: Adoptive transfer; Anti IL-12/23; Antibody; EAE; Oral proteins; Ustekinumab